Recruiting Team: « Liver cancers and Tumor invasion », at the Inserm/University of Bordeaux Unit 1312-BRIC

Project :
Our project is focused on Hepatoblastoma (HB), the most common malignant liver tumor in children. Our recent
data identified the FSCN1 gene, encoding Fascin-1, a new potential target in HB. We found that FSCN1 expression
is significantly higher in the poorly differentiated HB subtype. Moreover, our in vitro approach revealed that
Fascin-1 silencing is able to favor cellular differentiation of HB cells. Thus, based on these results, the project will
address i) how Fascin-1 may sustain its effects in HB tumor cells and ii) whether Fascin-1 is an actionable ßcatenin target in HB.
Techniques: molecular and cellular biology, proteomics, mouse and 3D culture models
Recent publications of the team: Gest, Sena et al., bioRxiv https://doi.org/10.1101/2021.04.21.440735. In revision – Basbous, et al., Cancer Gene Ther. 2022.
PMID: 35256752 – Sala M, et al., Oncogene, 2022. PMID: 35322197 – Javary et al., Liver International, 2021. PMID: 33792165 –
Dourthe et al., Hepatology, 2021. PMID: 33754354 – Basbous et al., Small GTPases, 2020 (review). PMID: 33054516 – Ezzoukhry, Henriet, et al. Nature Communications, 2018. PMID: 29795195

Candidate profile:
• PhD or MD/PhD with at least one first author publication
• Enthusiastic and highly motivated researcher with strong interest in cancer cell biology
• Ability to work with a good team spirit
• Candidates with competence in mouse handling, cellular and molecular biology or 3D cultures will be
prioritized.
Work environnement :
The candidate will benefit from the high-level scientific environment of the newly created BRIC Unit and of stateof-the-art technological platforms. The lab is located in Bordeaux, Southwestern France, an international tourist
destination for its architectural and cultural heritage and a world wine capital.
How to apply:
Interested candidates should send a CV, cover letter summarizing research interests, professional
experience, and career goals and the names of two referees to violaine.moreau@inserm.fr

Deadline for applications: December 9th, 2022

En savoir plus